Neoadjuvant SHR-A1811 and SHR-A1701 ± Pertuzumab for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma
Clinical trial NCT07716111 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07716111
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-16
- Primary completion
- 2027-08-31
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.